<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Beta agonists in asthma: Acute administration and prophylactic use</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Beta agonists in asthma: Acute administration and prophylactic use</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Beta agonists in asthma: Acute administration and prophylactic use</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert F Lemanske, Jr, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric Schauberger, DO, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bruce S Bochner, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 30, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Beta adrenergic drugs are the most potent bronchodilators approved for clinical use in asthma and obstructive lung disease. Among the beta agonists, the individual agents vary in their rapidity of onset and duration of action. Inhaled, short-acting, selective beta-2 adrenergic agonists are the traditional mainstay of acute asthma therapy, while inhaled, long-acting, selective beta-2 adrenergic agonists (in combination with inhaled glucocorticoids) play a role in long-term control of moderate to severe asthma [<a href="#rid1">1</a>].</p><p>The mechanism of action of beta adrenergic medications and their clinical use in the management of asthma will be reviewed here. The general approach to asthma management, the treatment of acute exacerbations of asthma, and an overview of the delivery of inhaled medications are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/547.html" rel="external">"An overview of asthma management"</a> and  <a class="medical medical_review" href="/z/d/html/552.html" rel="external">"Delivery of inhaled medication in adults"</a> and  <a class="medical medical_review" href="/z/d/html/119093.html" rel="external">"Acute exacerbations of asthma in adults: Emergency department and inpatient management", section on 'Inhaled beta-agonists'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">MECHANISM OF ACTION</span><span class="headingEndMark"> — </span>Beta-2 agonists were developed for treatment of asthma through modifications of the <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> molecule to allow selective interaction with beta-2 receptors on bronchial smooth muscle to achieve bronchodilation with less tachycardia associated with activation of beta-1 receptors on cardiac muscle.</p><p>Beta-2 receptors are G protein-coupled transmembrane receptors that activate the enzyme adenylyl cyclase [<a href="#rid2">2</a>]. Activation of adenylyl cyclase produces cyclic adenosine monophosphate (cAMP). The exact mechanism by which cAMP causes smooth muscle relaxation is not fully understood but likely involves activation of protein kinase A and changes in intracellular calcium concentrations. Activation of beta-2 receptors also affect potassium channels through a separate mechanism. The function of the beta-2 adrenergic receptor and the role of polymorphisms of the receptor in individual responses to beta agonists are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/539.html" rel="external">"Beta-2 adrenergic receptor dysfunction and polymorphism in asthma"</a>.)</p><p>Variations in the molecular structure of beta agonists affect the onset and duration of bronchodilation. As an example, prolongation of the bronchodilator effect (relative to <a class="drug drug_general" data-topicid="8578" href="/z/d/drug information/8578.html" rel="external">isoproterenol</a>) is achieved by modifications that reduce susceptibility to degradation by catechol O-methyl transferase (COMT) and monoamine oxidase [<a href="#rid3">3</a>]. In addition, the long, lipophilic side chains of long-acting beta-agonists (LABAs; eg, <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">formoterol</a> and <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">salmeterol</a>) attach to the plasma membrane and increase the duration of binding of the drugs to the adrenergic receptor.</p><p>The lipophilic side chain of <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">salmeterol</a> leads to incorporation of the drug into the cell membrane and activation of the beta adrenergic receptor through an alternate binding site, rather than the usual site in the aqueous surface of the cell membrane [<a href="#rid2">2</a>]. It is thought that accessing the alternate binding site deeper in the cell membrane slows the onset of action of salmeterol.</p><p>By contrast, <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">formoterol</a> has a different lipophilic side chain that gives it a rapid onset of action comparable to that of <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a> (also known as salbutamol) and enables use of formoterol in combination inhalers (with inhaled glucocorticoids) for both maintenance and rescue treatment (termed single maintenance and reliever therapy [SMART]) [<a href="#rid4">4</a>]. (See <a class="local">'Quick relief of asthma symptoms'</a> below.)</p><p>Beta-2 agonists also interact with beta adrenergic receptors on the surface of a variety of other cells that play a role in asthma pathogenesis. As examples, beta agonists have the potential to decrease mast cell mediator release, inhibit neutrophil, eosinophil, and lymphocyte functional responses, increase mucociliary transport, and affect vascular tone and edema formation [<a href="#rid3">3,5</a>]. (See  <a class="medical medical_review" href="/z/d/html/522.html" rel="external">"Pathogenesis of asthma"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">USE IN ACUTE EXACERBATIONS OF ASTHMA</span><span class="headingEndMark"> — </span>Short-acting beta-2 agonists (SABAs) are the drug of choice for acute treatment of asthma symptoms and exacerbations [<a href="#rid4">4,6,7</a>].</p><p class="headingAnchor" id="H2109930"><span class="h2">Heterogeneity of response</span><span class="headingEndMark"> — </span>The responsiveness to beta agonists varies among patients. While some patients respond promptly to SABA administration, other patients with asthma exacerbations appear to require substantially higher doses of beta agonists to achieve reversal of bronchoconstriction [<a href="#rid8">8,9</a>]. Repetitive or continuous administration of a SABA may be needed, particularly for patients with moderate to severe exacerbations [<a href="#rid6">6,7</a>]. The management of acute exacerbations of asthma is discussed separately. (See <a class="local">'Adverse effects'</a> below and  <a class="medical medical_review" href="/z/d/html/119093.html" rel="external">"Acute exacerbations of asthma in adults: Emergency department and inpatient management", section on 'Inhaled beta-agonists'</a>.)</p><p>The individual response to beta agonist therapy for an acute exacerbation of asthma is related to many factors, including:</p><p class="bulletIndent1"><span class="glyph">●</span>The relative contribution of bronchoconstriction versus airway inflammation and edema in producing the underlying airway obstruction; bronchoconstriction is usually more responsive whereas the other components are not.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Route of medication delivery (oral, inhaled, parenteral). (See <a class="local">'Route of delivery'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The triggering mechanism (exercise, allergen exposure, infection).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Concurrent medication and baseline frequency of beta agonist use. Downregulation of beta receptors can occur with frequent use of beta agonists. (See <a class="local">'Tolerance'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Age and proper device technique, since airway geometry and the ability to utilize various delivery systems are important factors in children.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Duration of symptoms; a longer duration of symptoms (eg, days rather than minutes) typically suggests concomitant airway inflammation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The outcome measure(s) used to evaluate the response, both subjective (eg, ease of breathing) and objective (eg, improvements in peak flow or spirometry).</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Route of delivery</span><span class="headingEndMark"> — </span>The route of delivery (eg, metered dose or dry powder inhaler, nebulized, oral, subcutaneous, intravenous) of the beta agonist is an important determinant of efficacy. It might be expected that oral or parenteral administration would be more effective than inhaled use, since mucous plugging might prevent adequate airway penetration of inhaled forms. However, studies evaluating the relative efficacy have shown that inhaled and subcutaneous routes are superior to oral therapy. (See  <a class="medical medical_review" href="/z/d/html/552.html" rel="external">"Delivery of inhaled medication in adults"</a> and  <a class="medical medical_review" href="/z/d/html/5737.html" rel="external">"Delivery of inhaled medication in children"</a> and  <a class="medical medical_review" href="/z/d/html/5736.html" rel="external">"Use of medication nebulizers in children"</a> and  <a class="medical medical_review" href="/z/d/html/5738.html" rel="external">"The use of inhaler devices in children"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Many patients report superior symptom relief following nebulized therapy compared with metered dose inhalation; however, objective pulmonary function data after equal drug dosages generally do not support a difference in physiologic response [<a href="#rid10">10,11</a>]. On the other hand, nebulizer therapy would be preferred for patients who are unable to cooperate effectively with use of a pressurized metered dose inhaler (pMDI) because of their agitation, coordination difficulties, severity of exacerbation, or other disability [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Oral beta agonists are avoided as higher doses are required to achieve a bronchodilator response comparable to inhaled preparations, and higher doses have a greater likelihood of systemic adverse effects [<a href="#rid3">3</a>]. Factors reducing efficacy of oral administration include poor absorption and rapid gastrointestinal metabolism. Further, the therapeutic effect is delayed; peak bronchodilation does not occur until two hours after ingestion [<a href="#rid12">12</a>], making oral administration appropriate only for mild to moderate asthmatic symptoms and perhaps in patients unable to use other delivery methods due to age or lack of immediate availability.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Overall, data do not support use of intravenous over inhaled beta-2 agonists, although there is some variability among studies [<a href="#rid7">7,13-17</a>]. A systematic review that analyzed data from three trials (104 patients) found limited evidence that intravenous beta-2 agonist shortened recovery time when added to inhaled beta-2 agonist in children presenting to an emergency department with acute asthma, but no benefit in a trial that included 29 adults with acute exacerbations [<a href="#rid18">18</a>]. Parenteral beta agonists are not recommended for adults, except in rare situations such as anaphylaxis manifesting as an asthma exacerbation or inability to use inhaled bronchodilators. (See  <a class="medical medical_review" href="/z/d/html/119093.html" rel="external">"Acute exacerbations of asthma in adults: Emergency department and inpatient management", section on 'Parenteral beta-agonists (epinephrine and terbutaline)'</a>.)</p><p></p><p class="bulletIndent1">Intravenous administration of beta agonists is clearly associated with the development of more severe adverse effects [<a href="#rid16">16-21</a>]. A higher incidence of tremor was noted in one study [<a href="#rid20">20</a>], and an elevated troponin was noted in 3 of 46 children in another study [<a href="#rid21">21</a>]. (See <a class="local">'Adverse effects'</a> below.)</p><p></p><p class="headingAnchor" id="H1487481"><span class="h2">Quick relief of asthma symptoms</span><span class="headingEndMark"> — </span>Quick relief of acute asthma symptoms (eg, shortness of breath, cough, wheeze, chest tightness) outside the hospital can usually be accomplished either with a SABA (eg, <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a>, <a class="drug drug_general" data-topicid="10215" href="/z/d/drug information/10215.html" rel="external">levalbuterol</a>) or the rapid-onset, long-acting beta-agonist (LABA) <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">formoterol</a>, in combination with an inhaled glucocorticoid  (<a class="graphic graphic_table graphicRef72467" href="/z/d/graphic/72467.html" rel="external">table 1</a>) [<a href="#rid4">4,6,7</a>].</p><p>Of note, the LABA <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">formoterol</a> has an onset of action similar to <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a> (5 to 20 minutes), so combination inhalers that contain inhaled glucocorticoid and formoterol (eg, <a class="drug drug_general" data-topicid="8524" href="/z/d/drug information/8524.html" rel="external">budesonide-formoterol</a>) can be used for relief of acute asthma symptoms in addition to long-term maintenance, termed single maintenance and reliever therapy (SMART; off-label in the United States) [<a href="#rid4">4,22,23</a>]. (See <a class="local">'Long-term maintenance therapy with LABAs'</a> below and  <a class="medical medical_review" href="/z/d/html/527.html" rel="external">"Initiating asthma therapy and monitoring in adolescents and adults", section on 'Low-dose maintenance and reliever therapy (MART)'</a> and  <a class="medical medical_review" href="/z/d/html/532.html" rel="external">"Ongoing monitoring and titration of asthma therapies in adolescents and adults", section on 'Patients using anti-inflammatory relievers alone (Step 1 or 2)'</a>.)</p><p>The maximum total daily dose of <a class="drug drug_general" data-topicid="8524" href="/z/d/drug information/8524.html" rel="external">budesonide-formoterol</a> should not exceed eight puffs (36 mcg) for ages 4 to 11 years and 12 inhalations (54 mcg) for ages 12 years and older. Patients are encouraged to contact their asthma specialist if they require eight or more inhalations of budesonide-formoterol in a day.</p><p>Similar to formoterol-ICS, patient-activated reliever-triggered corticosteroid strategy (PARTICS) involves the administration of ICS whenever a bronchodilator is used for immediate symptom relief. This "symptom-driven" approach appears more effective than as-needed <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a> alone, although data are more limited than for combination glucocorticoid-formoterol inhalers. Combination glucocorticoid-albuterol inhalers are increasingly available in many parts of the world. <a class="drug drug_general" data-topicid="140501" href="/z/d/drug information/140501.html" rel="external">Albuterol-budesonide</a> (90 mcg-80 mcg) has been approved in the United States for patients aged 18 years and older [<a href="#rid24">24</a>]; its maximum daily dose should not exceed twelve puffs in a day.</p><p>Escalating need for a SABA (eg, &gt;2 days per week or &gt;6 to 8 puffs per day or exceeding one canister per month) is a warning sign that the patient's underlying disease activity is inadequately controlled and that additional intervention is warranted  (<a class="graphic graphic_table graphicRef53233" href="/z/d/graphic/53233.html" rel="external">table 2</a>) [<a href="#rid6">6</a>]. In addition, data from the SABINA cohort studies demonstrate that SABA overuse is associated with increased exacerbation risk, asthma hospitalizations, and mortality [<a href="#rid25">25-28</a>].</p><p>The Global Initiative for Asthma guidelines advise that asthma in adolescents and adults should <strong>not</strong> be treated with a SABA alone due to the risks of SABA-only treatment, SABA overuse, and evidence for benefit of inhaled corticosteroids (ICS) [<a href="#rid7">7,29</a>]. By contrast, the National Asthma Education and Prevention Program (NAEPP) 2020 Update continues to support use of SABA for quick symptom relief. The advantages and disadvantages of these two approaches are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/527.html" rel="external">"Initiating asthma therapy and monitoring in adolescents and adults"</a> and  <a class="medical medical_review" href="/z/d/html/547.html" rel="external">"An overview of asthma management"</a>.)</p><p class="headingAnchor" id="H2109923"><span class="h2">Use in emergency department and hospital</span><span class="headingEndMark"> — </span>Preparations of inhaled beta agonists, associated delivery systems, and dosing guidelines for SABAs used in the emergency department and hospital are listed in the table  (<a class="graphic graphic_table graphicRef72467" href="/z/d/graphic/72467.html" rel="external">table 1</a>). As noted above, the response of patients with acute exacerbations of asthma to beta agonist therapy is variable. Nevertheless, a few initial guidelines can be proposed for asthmatic exacerbations severe enough to require presentation to the emergency department. Other aspects of treatment of asthma exacerbations are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/119093.html" rel="external">"Acute exacerbations of asthma in adults: Emergency department and inpatient management"</a> and  <a class="medical medical_review" href="/z/d/html/5740.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Emergency department management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>If the patient can demonstrate proper pMDI technique, two to eight inhalations of a SABA (such as <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a>) can be administered using a spacer or chamber device (eg, AeroChamber, InspirEase)  (<a class="graphic graphic_picture graphicRef58957" href="/z/d/graphic/58957.html" rel="external">picture 1</a> and <a class="graphic graphic_table graphicRef72467" href="/z/d/graphic/72467.html" rel="external">table 1</a>). Alternatively, the dry powder inhaler (DPI) preparation of albuterol can be administered without a spacer or chamber device. Therapy can be repeated every 20 minutes for 3 doses, if needed, then tapered depending on response to therapy. (See  <a class="medical medical_review" href="/z/d/html/559.html" rel="external">"The use of inhaler devices in adults"</a> and  <a class="medical medical_review" href="/z/d/html/5737.html" rel="external">"Delivery of inhaled medication in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the patient is unable to use the pMDI or DPI, does not exhibit a satisfactory clinical response, or if nebulizer treatment is preferred by patient or provider, the SABA is administered by nebulizer. Doses of SABAs for nebulization are provided in the table  (<a class="graphic graphic_table graphicRef72467" href="/z/d/graphic/72467.html" rel="external">table 1</a>). Within the range of doses, the higher doses and continuous nebulization are used for more severe exacerbations in a monitored setting. The cumulative dose should be monitored because of the potential adverse effects and should not exceed the recommended limits. (See <a class="local">'Heterogeneity of response'</a> above and <a class="local">'Adverse effects'</a> below and  <a class="medical medical_review" href="/z/d/html/552.html" rel="external">"Delivery of inhaled medication in adults", section on 'Continuous nebulization'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>SABAs may be mixed with <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a> for the initial management (first three hours) of severe exacerbations [<a href="#rid6">6,7</a>]. (See  <a class="medical medical_review" href="/z/d/html/119093.html" rel="external">"Acute exacerbations of asthma in adults: Emergency department and inpatient management", section on 'Inhaled muscarinic antagonists'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rarely, <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> (0.01 mg/kg to a maximum dose of 0.3 to 0.5 mg) is administered subcutaneously or intramuscularly if nebulized therapy is either unavailable, ineffective clinically, or anaphylaxis is suspected as a cause of the asthma flare. (See  <a class="medical medical_review" href="/z/d/html/119093.html" rel="external">"Acute exacerbations of asthma in adults: Emergency department and inpatient management", section on 'Parenteral beta-agonists (epinephrine and terbutaline)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intravenous beta agonist therapy, particularly with <a class="drug drug_general" data-topicid="8578" href="/z/d/drug information/8578.html" rel="external">isoproterenol</a>, is not recommended, since it has been associated with adverse cardiac effects [<a href="#rid3">3,19</a>]. (See <a class="local">'Route of delivery'</a> above and <a class="local">'Adverse effects'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beta agonist therapy is associated with a decrease in arterial oxygen tension (PaO<sub>2</sub>) of 5 mmHg or more, so supplemental oxygen is provided to maintain the pulse oxygen saturation above 90 percent (above 95 percent in pregnant women and patients with coexistent cardiac disease), for severe exacerbations, or when continuous measurement of pulse oximetry is not available [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/1612.html" rel="external">"Pulse oximetry"</a>.)</p><p></p><p class="headingAnchor" id="H448824211"><span class="h2">Levalbuterol</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">Albuterol</a> is a racemic mixture with a 1:1 ratio of the isomers R-albuterol (<a class="drug drug_general" data-topicid="10215" href="/z/d/drug information/10215.html" rel="external">levalbuterol</a>) and S-albuterol; the R-isomer is responsible for the drug's bronchodilating activity. It is hypothesized that the S-isomer of albuterol activates proconstrictive and proinflammatory pathways in bronchial smooth muscle cells [<a href="#rid30">30</a>], which would theoretically diminish the beneficial effects of the R-isomer (levalbuterol). However, the clinical importance of these detrimental effects is unclear [<a href="#rid31">31-36</a>] and do not provide a clinically significant advantage over racemic albuterol for most patients [<a href="#rid31">31,36-40</a>].</p><p class="headingAnchor" id="H1177614052"><span class="h1">PREVENTION OF ASTHMA SYMPTOMS</span></p><p class="headingAnchor" id="H7"><span class="h2">Allergen-induced asthma</span><span class="headingEndMark"> — </span>In immunoglobulin E (IgE) sensitized patients, relevant allergen exposure can elicit both an immediate (within minutes) bronchoconstrictive response and a late (hours) inflammatory response that is often accompanied by recurrent bronchoconstriction. When exposure is unavoidable, bronchoconstriction can be attenuated by use of a beta agonist prior to exposure. However, as pretreatment with a beta agonist does not block the initiation and/or propagation of airway inflammation by allergen or the resultant increase in bronchial hyperresponsiveness, allergen avoidance is always preferred over pretreatment. (See  <a class="medical medical_review" href="/z/d/html/530.html" rel="external">"Allergen avoidance in the treatment of asthma and allergic rhinitis"</a>.)</p><p>There are important differences in the ability of short- and long-acting beta-agonists to block early and late airway responses to allergen (see  <a class="medical medical_review" href="/z/d/html/522.html" rel="external">"Pathogenesis of asthma"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Short-acting beta-agonists (SABAs) given prior to exposure can attenuate the immediate response but are generally ineffective in preventing or reversing the late response [<a href="#rid41">41,42</a>], as they do not substantially inhibit the inflammatory response.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The long-acting beta-agonists (eg, <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">formoterol</a>, <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">salmeterol</a>, vilanterol) can block both the immediate- and late-phase bronchoconstrictive responses but not the inflammatory response (unless an inhaled glucocorticoid is given concomitantly) [<a href="#rid43">43</a>].</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Use in exercise-induced asthma</span><span class="headingEndMark"> — </span>SABAs are the traditional drug of choice for the prevention and treatment of exercise-induced bronchoconstriction (EIB) [<a href="#rid44">44-46</a>]. Combination inhalers containing glucocorticoid and <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">formoterol</a> (eg, <a class="drug drug_general" data-topicid="8524" href="/z/d/drug information/8524.html" rel="external">budesonide-formoterol</a>) are an effective alternate choice. (See  <a class="medical medical_review" href="/z/d/html/533.html" rel="external">"Exercise-induced bronchoconstriction"</a>.)</p><p class="headingAnchor" id="H179761390"><span class="h3">Proposed mechanisms</span><span class="headingEndMark"> — </span>Several mechanisms have been proposed to explain how beta agonists inhibit EIB:</p><p class="bulletIndent1"><span class="glyph">●</span>The bronchodilation that they induce before exercise may counterbalance the asthma induced by exercise.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The normal bronchodilator response seen within the first few minutes of exercise may be enhanced, thereby overriding or attenuating the airway obstruction that follows exercise.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The mediator release associated with EIB may be inhibited due to activation of mast cell beta adrenergic receptors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The effect of beta agonists on smooth muscle may prevent mediator-induced bronchoconstriction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beta agonists may increase bronchial blood flow, which would reduce the heat loss in the airway that is thought to be one of the mechanisms of EIB [<a href="#rid47">47,48</a>].</p><p></p><p class="headingAnchor" id="H9"><span class="h3">Efficacy of different preparations</span><span class="headingEndMark"> — </span>The ability of various beta agonists to inhibit or attenuate EIB is dependent upon the minute ventilation (workload) and the particular drug administered. SABAs such as <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a>, <a class="drug drug_general" data-topicid="10215" href="/z/d/drug information/10215.html" rel="external">levalbuterol</a>, or fenoterol attenuate EIB if taken 5 to 20 minutes before exercise. The duration of protection varies with the agent used. Albuterol may attenuate EIB for four to six hours [<a href="#rid49">49</a>], whereas other bata-agonists have different durations of protective effect [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/z/d/html/533.html" rel="external">"Exercise-induced bronchoconstriction", section on 'Pre-exercise treatments for EIB'</a>.)</p><p>The long-acting beta-agonists (LABAs) <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">salmeterol</a> and <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">formoterol</a> are also very effective in attenuating EIB [<a href="#rid51">51,52</a>]. However, single-agent LABA inhalers are avoided in asthma due to increased risks of exacerbations and mortality with LABA monotherapy (see <a class="local">'Evidence against LABA monotherapy'</a> below). Instead, a combination inhaler containing a glucocorticoid plus formoterol (eg, <a class="drug drug_general" data-topicid="8524" href="/z/d/drug information/8524.html" rel="external">budesonide-formoterol</a> 160 mcg/4.5 mcg) can be given one inhalation 5 to 20 minutes prior to exercise [<a href="#rid7">7</a>]. As one would expect, the duration of action of formoterol is longer than the SABAs; the mean duration of a 50 percent reduction in EIB is 6.5 hours with formoterol and 1.5 hours with <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a> [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/z/d/html/533.html" rel="external">"Exercise-induced bronchoconstriction", section on 'Pre-exercise treatments for EIB'</a>.)</p><p>We do not use the LABA <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">salmeterol</a> as monotherapy to prevent EIB, even though it produces significant bronchodilation for at least nine hours  (<a class="graphic graphic_figure graphicRef73033 graphicRef81068" href="/z/d/graphic/73033.html" rel="external">figure 1A-B</a>) [<a href="#rid52">52</a>], because it must be administered at least an hour before exercise for prevention and it is not useful for treatment of breakthrough symptoms. The duration of protection induced by the long-acting preparations may decrease with chronic use in the absence of concomitant inhaled glucocorticoid  (<a class="graphic graphic_figure graphicRef61821" href="/z/d/graphic/61821.html" rel="external">figure 2</a>) [<a href="#rid53">53</a>]. (See <a class="local">'Tolerance'</a> below.)</p><p>Low-dose inhaled corticosteroids (ICS)-SABA combination inhalers have been approved for use in some regions, including the United States [<a href="#rid24">24</a>]. A <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">budesonide</a>/<a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a> combination inhaler reduced bronchoconstriction postexercise compared with placebo (TYREE trial), consistent with the known effects of albuterol [<a href="#rid54">54</a>]. The National Asthma Education and Prevention Program (NAEPP) and Global Initiative for Asthma (GINA) guidelines include the alternative of combination ICS-SABA or low-dose ICS plus SABA taken concomitantly when needed for patients with Step 2/mild persistent asthma  (<a class="graphic graphic_table graphicRef127798" href="/z/d/graphic/127798.html" rel="external">table 3</a>).</p><p class="headingAnchor" id="H179761012"><span class="h1">LONG-TERM MAINTENANCE THERAPY WITH LABAs</span><span class="headingEndMark"> — </span>The long-acting beta-agonists (LABAs) <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">formoterol</a>, <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">salmeterol</a>, and vilanterol [<a href="#rid55">55</a>] are used in combination with inhaled glucocorticoids to improve asthma control and minimize the dose of inhaled glucocorticoids needed to achieve control  (<a class="graphic graphic_table graphicRef68143" href="/z/d/graphic/68143.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef57761" href="/z/d/graphic/57761.html" rel="external">table 5</a>) [<a href="#rid7">7</a>]. LABAs have additive effects with inhaled glucocorticoids when the two agents are used in combination [<a href="#rid56">56-59</a>]. The use of LABAs to treat persistent asthma and the safety of these medications for chronic maintenance therapy are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/532.html" rel="external">"Ongoing monitoring and titration of asthma therapies in adolescents and adults"</a> and  <a class="medical medical_review" href="/z/d/html/551.html" rel="external">"Treatment of severe asthma in adolescents and adults"</a>.)</p><p>As noted above, guidelines include the option of using combination inhalers containing glucocorticoid-formoterol for both maintenance and relief of acute asthma symptoms. (See <a class="local">'Quick relief of asthma symptoms'</a> above and  <a class="medical medical_review" href="/z/d/html/527.html" rel="external">"Initiating asthma therapy and monitoring in adolescents and adults", section on 'Low-dose maintenance and reliever therapy (MART)'</a> and  <a class="medical medical_review" href="/z/d/html/532.html" rel="external">"Ongoing monitoring and titration of asthma therapies in adolescents and adults", section on 'Increasing (stepping up) therapy, for persistent poor symptom control'</a>.)</p><p>In addition, a combination triple-therapy inhaler containing ICS, LABA, and a long-acting muscarinic antagonist (LAMA) is approved for the treatment of severe persistent asthma (eg, <a class="drug drug_general" data-topicid="114898" href="/z/d/drug information/114898.html" rel="external">fluticasone furoate-umeclidinium-vilanterol</a>). (See  <a class="medical medical_review" href="/z/d/html/551.html" rel="external">"Treatment of severe asthma in adolescents and adults", section on 'Inhaled GC/LAMA or GC/LAMA/LABA'</a>.)</p><p class="headingAnchor" id="H3451339769"><span class="h2">Evidence of LABA-ICS safety</span><span class="headingEndMark"> — </span>Clinical trials and systematic reviews have been increasingly reassuring with respect to the safety of LABAs when used with ICS in fixed-combination inhalers [<a href="#rid60">60-69</a>], in contrast to prior studies that had raised concerns about LABA safety [<a href="#rid70">70-74</a>]. The more recent data from sufficiently powered clinical trials have enabled the US Food and Drug Administration (FDA) to make a firm statement regarding the safety of LABAs when used in combination with ICS and to warn against the use of LABA monotherapy [<a href="#rid75">75</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>For adults, an analysis of the four FDA-mandated trials [<a href="#rid65">65,68,76,77</a>] comparing combination ICS plus LABA with ICS alone (36,010 participants) found that serious asthma-related adverse events (composite of hospitalization, intubation, or death) occurred in 119 of 18,004 participants (0.66 percent) taking the combination inhaler and in 108 of 18,006 participants (0.6 percent) taking ICS, for a relative risk (RR) of 1.09 (95% CI 0.83-1.43) [<a href="#rid69">69</a>]. Thus, combination therapy did not result in a significantly increased risk of serious adverse asthma events compared with ICS alone. A lower risk of asthma exacerbation was noted in the combination inhaler group compared with ICS alone (RR 0.83, 95% CI 0.78-0.89). A study comparing the safety and efficacy of SABA to LABA-ICS in stable asthmatics showed less systemic and cardiovascular adverse effects with combination therapy [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For children, a multicenter trial (VESTRI) randomly assigned 6208 children 4 to 11 years of age who had an asthma exacerbation in the previous year to a combination inhaler with <a class="drug drug_general" data-topicid="8951" href="/z/d/drug information/8951.html" rel="external">fluticasone</a> propionate (100 mcg or 250 mcg/inhalation) plus <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">salmeterol</a> or to monotherapy with fluticasone propionate (100 mcg or 250 mcg/inhalation), one inhalation twice daily for 26 weeks [<a href="#rid67">67</a>]. Serious adverse events (hospitalization due to asthma exacerbation) occurred in 27 of 3107 patients in the <a class="drug drug_general" data-topicid="8730" href="/z/d/drug information/8730.html" rel="external">fluticasone-salmeterol</a> group and in 23 of the 3101 patients in the fluticasone group, hazard ratio 1.28 (95% CI 0.73-2.27). No deaths or endotracheal intubations were reported. This hazard ratio suggests that the risk of serious asthma-related events was similar between the two groups.</p><p></p><p>These studies support the stepwise approach to asthma outlined in national and international guidelines [<a href="#rid4">4,6,7,79</a>]. (See  <a class="medical medical_review" href="/z/d/html/547.html" rel="external">"An overview of asthma management"</a>.)</p><p class="headingAnchor" id="H2977170776"><span class="h2">Glucocorticoid-sparing effect</span><span class="headingEndMark"> — </span>A glucocorticoid-sparing effect refers to the ability of a pharmacologic agent to permit ICS dose reduction following its addition to a pre-existing ICS regimen. The efficacy of chronic LABAs as glucocorticoid-sparing agents was examined in a meta-analysis of 10 randomized trials comparing high-dose ICS versus combined low-dose ICS plus chronic LABA [<a href="#rid80">80</a>]. Addition of a chronic LABA permitted 37 to 60 percent reduction of the ICS dose without deterioration of asthma control.</p><p>Other studies have confirmed the efficacy of LABAs as glucocorticoid-sparing agents [<a href="#rid81">81,82</a>]. Tapering of the ICS was associated with increased sputum eosinophils in one study, but this was not accompanied by increased symptoms.</p><p class="headingAnchor" id="H1836654421"><span class="h2">Ultra long-acting beta-agonists</span><span class="headingEndMark"> — </span>Once-daily LABAs (24-hour duration of action), such as <a class="drug drug_general" data-topicid="16792" href="/z/d/drug information/16792.html" rel="external">indacaterol</a>, <a class="drug drug_general" data-topicid="96482" href="/z/d/drug information/96482.html" rel="external">olodaterol</a>, and vilanterol [<a href="#rid83">83-87</a>], have been approved by the FDA for use in patients with chronic obstructive pulmonary disease (COPD), but only vilanterol is approved for use in patients with asthma.</p><p>Clinically important tolerance seems unlikely during combined treatment with vilanterol and ICS, based on a randomized trial that compared <a class="drug drug_general" data-topicid="89424" href="/z/d/drug information/89424.html" rel="external">fluticasone furoate-vilanterol</a> (varying doses) with placebo once daily in 613 patients with asthma [<a href="#rid84">84</a>]. After 28 days, no significant diminution was noted in the mean FEV<sub>1</sub> after salbutamol (<a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a>) in the fluticasone furoate-vilanterol groups relative to placebo.</p><p class="headingAnchor" id="H879212045"><span class="h2">Evidence against LABA monotherapy</span><span class="headingEndMark"> — </span>While LABAs reduce asthma symptoms and reduce airflow limitation in the short term, LABAs <strong>should not</strong> be prescribed as monotherapy for asthma [<a href="#rid4">4,7,75,79,88,89</a>].</p><p>Several systematic reviews have concluded that LABA monotherapy increases the risk of serious adverse events (SAEs) compared with placebo [<a href="#rid90">90-92</a>]. In a systematic review and meta-analysis (72,092 subjects), LABA monotherapy was associated with an increased risk of asthma-related death (RR 3.83, 95% CI 1.21-12.14), particularly in children, in subjects receiving <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">salmeterol</a>, and when the duration of treatment was &gt;12 weeks [<a href="#rid91">91</a>]. However, LABA monotherapy reduced exacerbations requiring oral glucocorticoids. In a separate systematic review (22 studies, 8032 participants), <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">formoterol</a> monotherapy was associated with an increase in SAEs compared with placebo, particularly in children (odds ratio [OR] 1.57; 95% CI 1.06-2.31); the difference in deaths was not significant [<a href="#rid90">90</a>].</p><p class="headingAnchor" id="H12"><span class="h1">TOLERANCE</span><span class="headingEndMark"> — </span>Decreased sensitivity to beta agonists with chronic use (also known as tolerance or tachyphylaxis) has been identified in laboratory studies and is believed to be primarily mediated by downregulation of beta-2 adrenergic receptors [<a href="#rid2">2,93</a>]. However, the clinical importance of this effect is unclear. Most investigators believe that the duration of action of the bronchodilator response is affected more than the peak effect [<a href="#rid3">3</a>] and that oral routes are more likely to induce tolerance than inhaled methods of delivery. Baseline levels of airway inflammation and beta-2 adrenergic receptor polymorphisms appear to influence this effect. (See  <a class="medical medical_review" href="/z/d/html/539.html" rel="external">"Beta-2 adrenergic receptor dysfunction and polymorphism in asthma", section on 'Receptor polymorphisms'</a>.)</p><p>Based on the expectation that longer duration of action (and thus more continuous stimulation of the beta receptors) would increase the development of tolerance, long-acting beta-agonists (LABAs; eg, <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">formoterol</a>, <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">salmeterol</a>) would be more likely to induce tolerance than shorter-acting agents. However, clinical studies have yielded mixed results.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Salmeterol</strong><strong> and tolerance</strong> – One randomized trial found that 12 weeks of regular therapy with <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">salmeterol</a> did not result in a diminution in bronchodilating efficacy or a change in the use of rescue <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a> therapy  (<a class="graphic graphic_figure graphicRef78242" href="/z/d/graphic/78242.html" rel="external">figure 3</a>) [<a href="#rid94">94</a>]. In this trial, 234 patients were assigned to receive regularly scheduled LABA (salmeterol), short-acting beta-agonist (SABA; eg, albuterol), or placebo  (<a class="graphic graphic_figure graphicRef78242" href="/z/d/graphic/78242.html" rel="external">figure 3</a>) [<a href="#rid94">94</a>]. Salmeterol was more effective at increasing the morning peak expiratory flow rate than albuterol or placebo (+24, -6, +1 L/min, respectively, p&lt;0.001). The mean overall symptom score was improved most by salmeterol treatment (p&lt;0.05), with the number of days with symptoms and of nights with awakenings decreasing by 22 percent and 52 percent, respectively.</p><p></p><p class="bulletIndent1">By contrast, other reports have noted a decrease in the ability of <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">salmeterol</a> to protect against a bronchoconstrictive stimulus following a similar duration of salmeterol therapy  (<a class="graphic graphic_figure graphicRef61821" href="/z/d/graphic/61821.html" rel="external">figure 2</a>) [<a href="#rid53">53,95-98</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Formoterol</strong><strong> and tolerance</strong> – Chronic use of <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">formoterol</a> reduced the acute bronchodilator response to <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a> following methacholine-induced bronchoconstriction in a small study [<a href="#rid99">99</a>]. Bronchodilator tolerance occurred after one dose of formoterol and progressively increased with longer durations of formoterol dosing up to one week. Tolerance resolved three days after discontinuation of the formoterol.</p><p></p><p>A greater degree of airway inflammation may increase the induction of tolerance to LABAs. Since baseline levels of exhaled nitric oxide (FeNO) may be a surrogate biomarker for the presence of increased airway inflammation [<a href="#rid100">100</a>], these relationships were examined in study of 26 subjects not on controller therapy for asthma who underwent exercise challenge testing before and after two weeks of <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">salmeterol</a> monotherapy [<a href="#rid101">101</a>]. A 74±13 percent loss of bronchoprotection was noted among subjects with a FeNO greater than 50 ppb (consistent with eosinophilic airway inflammation) in contrast to a 7±16 percent gain in bronchoprotection among those with a FeNO less than 25 ppb. This observation lends support to the practice of avoiding monotherapy with LABAs and suggests that any observed reductions in bronchoprotection with chronic LABA use may be a reflection of the degree of airway inflammation. (See  <a class="medical medical_review" href="/z/d/html/542.html" rel="external">"Exhaled nitric oxide analysis and applications"</a>.)</p><p>In addition to a potential problem with tolerance, chronic reliance on beta agonist inhalers may disadvantage patients whose disease process involves mechanisms other than bronchial smooth muscle constriction, such as bronchial wall inflammation. Without proper recognition and intervention, patients may use more short-acting beta-agonist (SABA) inhalations at progressively more frequent intervals to obtain symptom relief. This overuse has the disadvantages of delaying addition of other therapeutic agents (such as antiinflammatory drugs) that can reverse or attenuate other important pathophysiologic factors, such as airway edema, mucus secretion, and inflammation.</p><p class="headingAnchor" id="H179762302"><span class="h1">ADVERSE EFFECTS</span><span class="headingEndMark"> — </span>Beta agonists are associated with several side effects including the following [<a href="#rid102">102</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tremor</strong> – Tremor is the most frequent acute side effect and is more noticeable with oral therapy than with inhaled agents. Patient acceptance of tremor is often related to diminished awareness of the tremor due to decreased peak-trough variations over time [<a href="#rid3">3,103</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tachycardia and palpitations</strong> – Increased heart rate and palpitations are dose-dependent and are less common with the inhaled selective beta-2 agonists (such as <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a>) than with nonselective agents. Use of a spacer or chamber device reduces these side effects by reducing oral deposition of medication, which contributes to side effects but not bronchodilation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stress cardiomyopathy</strong> – Stress-induced (takotsubo) cardiomyopathy has been associated with treatment of status asthmaticus in case reports [<a href="#rid104">104-106</a>]. (See  <a class="medical medical_review" href="/z/d/html/3494.html" rel="external">"Clinical manifestations and diagnosis of stress (takotsubo) cardiomyopathy", section on 'Role of catecholamines'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolic disturbances</strong> – Metabolic disturbances, such as transient decrease in serum potassium, phosphate, and magnesium, and increase in serum glucose, are also well-known adverse effects, although they are rarely of clinical significance [<a href="#rid107">107-110</a>].</p><p></p><p>In some patients, <a class="drug drug_general" data-topicid="10215" href="/z/d/drug information/10215.html" rel="external">levalbuterol</a> may reduce the incidence of tachycardia and mild hypokalemia compared with <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a> (a racemic mixture) [<a href="#rid33">33</a>], although the clinical importance of this possible difference is uncertain. (See  <a class="medical medical_review" href="/z/d/html/2341.html" rel="external">"Causes of hypokalemia in adults", section on 'Elevated beta-adrenergic activity'</a>.)</p><p class="headingAnchor" id="H695278900"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112325.html" rel="external">"Society guideline links: Asthma in adolescents and adults"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15344.html" rel="external">"Patient education: Asthma in children (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/15343.html" rel="external">"Patient education: Asthma in adults (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16117.html" rel="external">"Patient education: Medicines for asthma (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16113.html" rel="external">"Patient education: How to use your metered dose inhaler (adults) (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/371.html" rel="external">"Patient education: Asthma treatment in adolescents and adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/373.html" rel="external">"Patient education: Trigger avoidance in asthma (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/366.html" rel="external">"Patient education: How to use a peak flow meter (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/369.html" rel="external">"Patient education: Inhaler techniques in adults (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of action</strong> – Beta adrenergic agonists are the most potent and rapidly acting bronchodilator medications available for asthma treatment. Beta agonists interact with beta adrenergic receptors on a variety of cells to relax bronchial smooth muscle, decrease mast cell mediator release, inhibit neutrophil, eosinophil, and lymphocyte functional responses, increase mucociliary transport, and affect vascular tone and edema formation. (See <a class="local">'Mechanism of action'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Short-acting beta-agonists</strong> – The primary use of short-acting beta-agonists (SABAs) is the quick relief of acute asthma symptoms (eg, shortness of breath, cough, wheeze, chest tightness). SABAs (eg, <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a>, <a class="drug drug_general" data-topicid="10215" href="/z/d/drug information/10215.html" rel="external">levalbuterol</a>) are prescribed for use as needed, rather than on a routine basis. Acute exacerbations of asthma are heterogeneous, and the response to therapy is not uniformly predictable. Inhaled and systemic beta agonist preparations, delivery systems, and dosing guidelines are listed in the tables  (<a class="graphic graphic_table graphicRef72467" href="/z/d/graphic/72467.html" rel="external">table 1</a>). (See <a class="local">'Use in acute exacerbations of asthma'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute exacerbations</strong> – Inhaled SABAs (such as <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a>) remain the drug of choice for asthma exacerbations requiring emergency department treatment. Those who can demonstrate proper technique for using a pressurized metered dose inhaler (pMDI) are initially treated with two to eight inhalations of a SABA administered from a pMDI using a spacer or chamber device (eg, AeroChamber, InspirEase)  (<a class="graphic graphic_picture graphicRef58957" href="/z/d/graphic/58957.html" rel="external">picture 1</a>). Alternatively, albuterol is administered by nebulizer  (<a class="graphic graphic_table graphicRef72467" href="/z/d/graphic/72467.html" rel="external">table 1</a>). SABA MDI or nebulizer therapy can be repeated in 30 to 60 minutes until maximal improvement in pulmonary function can be demonstrated. (See <a class="local">'Use in acute exacerbations of asthma'</a> above and  <a class="medical medical_review" href="/z/d/html/119093.html" rel="external">"Acute exacerbations of asthma in adults: Emergency department and inpatient management", section on 'Inhaled beta-agonists'</a>.)</p><p></p><p class="bulletIndent1">If a satisfactory clinical response to pMDI administration of a SABA is not achieved or if the exacerbation is severe, a SABA is administered by nebulizer, either as individual treatments every 20 minutes or as a continuous treatment (eg, for more severe exacerbations); the doses are listed in the table  (<a class="graphic graphic_table graphicRef72467" href="/z/d/graphic/72467.html" rel="external">table 1</a>). (See <a class="local">'Use in emergency department and hospital'</a> above and  <a class="medical medical_review" href="/z/d/html/552.html" rel="external">"Delivery of inhaled medication in adults", section on 'Continuous nebulization'</a>.)</p><p></p><p class="bulletIndent1">Rarely, <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> (0.01 mg/kg to a maximum dose of 0.3 mg) is administered subcutaneously or intramuscularly to treat acute asthma exacerbations and is reserved for patients with concomitant anaphylaxis or times when nebulized therapy is either unavailable or ineffective clinically. (See <a class="local">'Use in acute exacerbations of asthma'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment and allergen exposure</strong> – Despite the ability of beta agonists to prevent or attenuate allergen-induced bronchoconstriction, avoidance of allergen exposure by sensitized patients is always preferred over pretreatment with a SABA. Pretreatment does not block the airway inflammation and resultant increase in bronchial hyperresponsiveness associated with allergen exposure. (See <a class="local">'Allergen-induced asthma'</a> above and  <a class="medical medical_review" href="/z/d/html/530.html" rel="external">"Allergen avoidance in the treatment of asthma and allergic rhinitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exercise-induced bronchoconstriction (EIB)</strong> – SABAs and combination inhalers with glucocorticoid and <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">formoterol</a> are effective in both treatment and prevention of EIB. (See <a class="local">'Use in exercise-induced asthma'</a> above and  <a class="medical medical_review" href="/z/d/html/533.html" rel="external">"Exercise-induced bronchoconstriction", section on 'Selection of pharmacologic therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Controller therapy for asthma</strong> – Long-acting beta-agonists (LABAs) are used in combination with inhaled glucocorticoids for patients with persistent asthma. The LABA <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">formoterol</a> has a rapid onset of action (similar to <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a>); combination inhalers containing glucocorticoid-formoterol can be used in some settings for relief of acute symptoms and for maintenance (off-label in the United States). LABAs should never be prescribed as monotherapy. (See <a class="local">'Long-term maintenance therapy with LABAs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tolerance</strong> – Decreased sensitivity, also called tolerance (tachyphylaxis), to beta agonists may occur with chronic, frequent use of beta agonists. The effect appears primarily mediated by downregulation of beta-2 adrenergic receptors, such that increasing agonist doses are required for the same degree of bronchodilation. The clinical significance of tolerance largely relates to patients who overuse beta agonist inhalers, rather than appropriately avoiding the relevant exposure (eg, allergen) or adding appropriate antiinflammatory controller medication. (See <a class="local">'Tolerance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Tremor is the most frequent acute side effect associated with beta agonists. Other side effects include palpitations, tachycardia, metabolic disturbances, and rarely stress-induced (takotsubo) cardiomyopathy. (See <a class="local">'Adverse effects'</a> above and  <a class="medical medical_review" href="/z/d/html/3494.html" rel="external">"Clinical manifestations and diagnosis of stress (takotsubo) cardiomyopathy"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Cazzola M, Page CP, Rogliani P, Matera MG. β2-agonist therapy in lung disease. Am J Respir Crit Care Med 2013; 187:690.</a></li><li><a class="nounderline abstract_t">Johnson M. Beta2-adrenoceptors: mechanisms of action of beta2-agonists. Paediatr Respir Rev 2001; 2:57.</a></li><li class="breakAll">Sorkness CA. Beta-adrenergic Agonists. In: Middleton's Allergy: Principles and Practice, 7th ed, Adkinson NF, Bochner BS, Busse WW, et al (Eds), Mosby, Philadelphia 2009. p.1485-503.</li><li><a class="nounderline abstract_t">Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC), Cloutier MM, Baptist AP, et al. 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol 2020; 146:1217.</a></li><li><a class="nounderline abstract_t">Johnson M. Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation. J Allergy Clin Immunol 2006; 117:18.</a></li><li class="breakAll">National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on May 31, 2016).</li><li class="breakAll">2023 Global Initiative for Asthma (GINA) Report: Global Strategy for Asthma Management and Prevention. www.ginasthma.org/2023-gina-main-report (Accessed on May 15, 2023).</li><li><a class="nounderline abstract_t">Tipton WR, Nelson HS. Frequent parenteral terbutaline in the treatment of status asthmaticus in children. Ann Allergy 1987; 58:252.</a></li><li><a class="nounderline abstract_t">Schuh S, Parkin P, Rajan A, et al. High-versus low-dose, frequently administered, nebulized albuterol in children with severe, acute asthma. Pediatrics 1989; 83:513.</a></li><li><a class="nounderline abstract_t">Colacone A, Afilalo M, Wolkove N, Kreisman H. A comparison of albuterol administered by metered dose inhaler (and holding chamber) or wet nebulizer in acute asthma. Chest 1993; 104:835.</a></li><li><a class="nounderline abstract_t">Idris AH, McDermott MF, Raucci JC, et al. Emergency department treatment of severe asthma. Metered-dose inhaler plus holding chamber is equivalent in effectiveness to nebulizer. Chest 1993; 103:665.</a></li><li><a class="nounderline abstract_t">Wolfe JD, Yamate M, Biedermann AA, Chu TJ. Comparison of the acute cardiopulmonary effects of oral albuterol, metaproterenol, and terbutaline in asthmatics. JAMA 1985; 253:2068.</a></li><li><a class="nounderline abstract_t">Fanta CH, Rossing TH, McFadden ER Jr. Treatment of acute asthma. Is combination therapy with sympathomimetics and methylxanthines indicated? Am J Med 1986; 80:5.</a></li><li><a class="nounderline abstract_t">Appel D, Karpel JP, Sherman M. Epinephrine improves expiratory flow rates in patients with asthma who do not respond to inhaled metaproterenol sulfate. J Allergy Clin Immunol 1989; 84:90.</a></li><li><a class="nounderline abstract_t">Williams S, Seaton A. Intravenous or inhaled salbutamol in severe acute asthma? Thorax 1977; 32:555.</a></li><li><a class="nounderline abstract_t">Pierce RJ, Payne CR, Williams SJ, et al. Comparison of intravenous and inhaled terbutaline in the treatment of asthma. Chest 1981; 79:506.</a></li><li><a class="nounderline abstract_t">Salmeron S, Brochard L, Mal H, et al. Nebulized versus intravenous albuterol in hypercapnic acute asthma. A multicenter, double-blind, randomized study. Am J Respir Crit Care Med 1994; 149:1466.</a></li><li><a class="nounderline abstract_t">Travers AH, Milan SJ, Jones AP, et al. Addition of intravenous beta(2)-agonists to inhaled beta(2)-agonists for acute asthma. Cochrane Database Syst Rev 2012; 12:CD010179.</a></li><li><a class="nounderline abstract_t">Maguire JF, O'Rourke PP, Colan SD, et al. Cardiotoxicity during treatment of severe childhood asthma. Pediatrics 1991; 88:1180.</a></li><li><a class="nounderline abstract_t">Browne GJ, Penna AS, Phung X, Soo M. Randomised trial of intravenous salbutamol in early management of acute severe asthma in children. Lancet 1997; 349:301.</a></li><li><a class="nounderline abstract_t">Bogie AL, Towne D, Luckett PM, et al. Comparison of intravenous terbutaline versus normal saline in pediatric patients on continuous high-dose nebulized albuterol for status asthmaticus. Pediatr Emerg Care 2007; 23:355.</a></li><li><a class="nounderline abstract_t">Grembiale RD, Pelaia G, Naty S, et al. Comparison of the bronchodilating effects of inhaled formoterol, salmeterol and salbutamol in asthmatic patients. Pulm Pharmacol Ther 2002; 15:463.</a></li><li><a class="nounderline abstract_t">Kips JC, Pauwels RA. Long-acting inhaled beta(2)-agonist therapy in asthma. Am J Respir Crit Care Med 2001; 164:923.</a></li><li class="breakAll">FDA approval of albuterol-budesonide MDI https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/214070Orig1s000ltr.pdf (Accessed on January 13, 2023).</li><li><a class="nounderline abstract_t">Janson C, Menzies-Gow A, Nan C, et al. SABINA: An Overview of Short-Acting β2-Agonist Use in Asthma in European Countries. Adv Ther 2020; 37:1124.</a></li><li><a class="nounderline abstract_t">Nwaru BI, Ekström M, Hasvold P, et al. Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J 2020; 55.</a></li><li><a class="nounderline abstract_t">Bateman ED, Price DB, Wang HC, et al. Short-acting β2-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study. Eur Respir J 2022; 59.</a></li><li><a class="nounderline abstract_t">Quint JK, Arnetorp S, Kocks JWH, et al. Short-Acting Beta-2-Agonist Exposure and Severe Asthma Exacerbations: SABINA Findings From Europe and North America. J Allergy Clin Immunol Pract 2022; 10:2297.</a></li><li><a class="nounderline abstract_t">Reddel HK, Bacharier LB, Bateman ED, et al. Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. J Allergy Clin Immunol Pract 2022; 10:S1.</a></li><li><a class="nounderline abstract_t">Agrawal DK, Ariyarathna K, Kelbe PW. (S)-Albuterol activates pro-constrictory and pro-inflammatory pathways in human bronchial smooth muscle cells. J Allergy Clin Immunol 2004; 113:503.</a></li><li><a class="nounderline abstract_t">Hamilos DL, D'Urzo A, Levy RJ, et al. Long-term safety study of levalbuterol administered via metered-dose inhaler in patients with asthma. Ann Allergy Asthma Immunol 2007; 99:540.</a></li><li><a class="nounderline abstract_t">Gawchik SM, Saccar CL, Noonan M, et al. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. J Allergy Clin Immunol 1999; 103:615.</a></li><li><a class="nounderline abstract_t">Handley DA, Tinkelman D, Noonan M, et al. Dose-response evaluation of levalbuterol versus racemic albuterol in patients with asthma. J Asthma 2000; 37:319.</a></li><li><a class="nounderline abstract_t">Tripp K, McVicar WK, Nair P, et al. A cumulative dose study of levalbuterol and racemic albuterol administered by hydrofluoroalkane-134a metered-dose inhaler in asthmatic subjects. J Allergy Clin Immunol 2008; 122:544.</a></li><li><a class="nounderline abstract_t">Nelson HS, Bensch G, Pleskow WW, et al. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol 1998; 102:943.</a></li><li><a class="nounderline abstract_t">Lötvall J, Palmqvist M, Arvidsson P, et al. The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients. J Allergy Clin Immunol 2001; 108:726.</a></li><li><a class="nounderline abstract_t">Ahrens R, Weinberger M. Levalbuterol and racemic albuterol: are there therapeutic differences? J Allergy Clin Immunol 2001; 108:681.</a></li><li><a class="nounderline abstract_t">Levalbuterol for asthma. Med Lett Drugs Ther 1999; 41:51.</a></li><li><a class="nounderline abstract_t">Datta D, Vitale A, Lahiri B, ZuWallack R. An evaluation of nebulized levalbuterol in stable COPD. Chest 2003; 124:844.</a></li><li><a class="nounderline abstract_t">Qureshi F, Zaritsky A, Welch C, et al. Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma. Ann Emerg Med 2005; 46:29.</a></li><li><a class="nounderline abstract_t">Cockcroft DW, Murdock KY. Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine. J Allergy Clin Immunol 1987; 79:734.</a></li><li><a class="nounderline abstract_t">Howarth PH, Durham SR, Lee TH, et al. Influence of albuterol, cromolyn sodium and ipratropium bromide on the airway and circulating mediator responses to allergen bronchial provocation in asthma. Am Rev Respir Dis 1985; 132:986.</a></li><li><a class="nounderline abstract_t">Twentyman OP, Finnerty JP, Harris A, et al. Protection against allergen-induced asthma by salmeterol. Lancet 1990; 336:1338.</a></li><li><a class="nounderline abstract_t">Bundgaard A, Buch D, Schmidt A, Bach-Mortensen N. Pretreatment of exercise-induced asthma in children using disodium cromoglycate and fenoterol inhalation powder. Eur J Respir Dis Suppl 1983; 130:36.</a></li><li><a class="nounderline abstract_t">Rohr AS, Siegel SC, Katz RM, et al. A comparison of inhaled albuterol and cromolyn in the prophylaxis of exercise-induced bronchospasm. Ann Allergy 1987; 59:107.</a></li><li><a class="nounderline abstract_t">Boulet LP, Turcotte H, Tennina S. Comparative efficacy of salbutamol, ipratropium, and cromoglycate in the prevention of bronchospasm induced by exercise and hyperosmolar challenges. J Allergy Clin Immunol 1989; 83:882.</a></li><li><a class="nounderline abstract_t">McFadden ER Jr. Hypothesis: exercise-induced asthma as a vascular phenomenon. Lancet 1990; 335:880.</a></li><li><a class="nounderline abstract_t">Anderson SD, Daviskas E. The airway microvasculature and exercise induced asthma. Thorax 1992; 47:748.</a></li><li><a class="nounderline abstract_t">Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992; 326:501.</a></li><li><a class="nounderline abstract_t">Sly RM, Heimlich EM, Ginsburg J, et al. Exercise-induced bronchospasm: evaluation of metaproterenol. Ann Allergy 1968; 26:253.</a></li><li><a class="nounderline abstract_t">Henriksen JM, Agertoft L, Pedersen S. Protective effect and duration of action of inhaled formoterol and salbutamol on exercise-induced asthma in children. J Allergy Clin Immunol 1992; 89:1176.</a></li><li><a class="nounderline abstract_t">Green CP, Price JF. Prevention of exercise induced asthma by inhaled salmeterol xinafoate. Arch Dis Child 1992; 67:1014.</a></li><li><a class="nounderline abstract_t">Ramage L, Lipworth BJ, Ingram CG, et al. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med 1994; 88:363.</a></li><li><a class="nounderline abstract_t">LaForce C, Chipps BE, Albers FC, et al. Albuterol/budesonide for the treatment of exercise-induced bronchoconstriction in patients with asthma: The TYREE study. Ann Allergy Asthma Immunol 2022; 128:169.</a></li><li><a class="nounderline abstract_t">Dwan K, Milan SJ, Bax L, et al. Vilanterol and fluticasone furoate for asthma. Cochrane Database Syst Rev 2016; 9:CD010758.</a></li><li><a class="nounderline abstract_t">Greenstone IR, Ni Chroinin MN, Masse V, et al. Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev 2005; :CD005533.</a></li><li><a class="nounderline abstract_t">Ni Chroinin M, Greenstone IR, Danish A, et al. Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database Syst Rev 2005; :CD005535.</a></li><li><a class="nounderline abstract_t">O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171:129.</a></li><li><a class="nounderline abstract_t">Lemanske RF Jr, Mauger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 2010; 362:975.</a></li><li><a class="nounderline abstract_t">Nelson H, Bonuccelli C, Radner F, et al. Safety of formoterol in patients with asthma: combined analysis of data from double-blind, randomized controlled trials. J Allergy Clin Immunol 2010; 125:390.</a></li><li><a class="nounderline abstract_t">Cates CJ, Jaeschke R, Schmidt S, Ferrer M. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2013; :CD006922.</a></li><li><a class="nounderline abstract_t">Salpeter SR, Wall AJ, Buckley NS. Long-acting beta-agonists with and without inhaled corticosteroids and catastrophic asthma events. Am J Med 2010; 123:322.</a></li><li><a class="nounderline abstract_t">Cates CJ, Jaeschke R, Schmidt S, Ferrer M. Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2013; :CD006924.</a></li><li><a class="nounderline abstract_t">Cates CJ, Wieland LS, Oleszczuk M, Kew KM. Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews. Cochrane Database Syst Rev 2014; :CD010314.</a></li><li><a class="nounderline abstract_t">Stempel DA, Raphiou IH, Kral KM, et al. Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone. N Engl J Med 2016; 374:1822.</a></li><li><a class="nounderline abstract_t">Wells KE, Peterson EL, Ahmedani BK, et al. The relationship between combination inhaled corticosteroid and long-acting β-agonist use and severe asthma exacerbations in a diverse population. J Allergy Clin Immunol 2012; 129:1274.</a></li><li><a class="nounderline abstract_t">Stempel DA, Szefler SJ, Pedersen S, et al. Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma. N Engl J Med 2016; 375:840.</a></li><li><a class="nounderline abstract_t">Peters SP, Bleecker ER, Canonica GW, et al. Serious Asthma Events with Budesonide plus Formoterol vs. Budesonide Alone. N Engl J Med 2016; 375:850.</a></li><li><a class="nounderline abstract_t">Busse WW, Bateman ED, Caplan AL, et al. Combined Analysis of Asthma Safety Trials of Long-Acting β2-Agonists. N Engl J Med 2018; 378:2497.</a></li><li><a class="nounderline abstract_t">Sears MR, Ottosson A, Radner F, Suissa S. Long-acting beta-agonists: a review of formoterol safety data from asthma clinical trials. Eur Respir J 2009; 33:21.</a></li><li><a class="nounderline abstract_t">Wijesinghe M, Weatherall M, Perrin K, et al. Risk of mortality associated with formoterol: a systematic review and meta-analysis. Eur Respir J 2009; 34:803.</a></li><li><a class="nounderline abstract_t">Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993; 306:1034.</a></li><li><a class="nounderline abstract_t">Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129:15.</a></li><li><a class="nounderline abstract_t">Walters EH, Gibson PG, Lasserson TJ, Walters JA. Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. Cochrane Database Syst Rev 2007; :CD001385.</a></li><li class="breakAll">FDA Drug Safety Communication: FDA review finds no significant increase in risk of serious asthma outcomes with long-acting beta agonists (LABAs) used in combination with inhaled corticosteroids (ICS) https://www.fda.gov/Drugs/DrugSafety/ucm589587.htm?utm_campaign=Long-Acting%20Beta%20agonists%20%28LABAs%29%20and%20Inhaled%20Corticosteroids%20%28ICS%29&amp;utm_medium=email&amp;utm_source=Eloqua&amp;elqTrackId=de90a40b47ac46f49cbfedb9752d9a88&amp;elq=62c18bc18584487f8d6f06c9c1554121&amp;elqaid=1864&amp;elqat=1&amp;elqCampaig (Accessed on December 21, 2017).</li><li><a class="nounderline abstract_t">Weinstein CLJ, Gates D, Ryan N, et al. Serious asthma outcomes with mometasone furoate plus formoterol versus mometasone alone. Am J Respir Crit Care Med 2017; 195:A7612.</a></li><li class="breakAll">U.S. National Library of Medicine (clinicaltrials.gov). Clinical Study of Safety of Foradil in Patients With Persistent Asthma (Unpublished study sponsored by Novartis). https://clinicaltrials.gov/ct2/show/NCT01845025 (Accessed on June 28, 2018).</li><li><a class="nounderline abstract_t">Kearns N, Bruce P, Williams M, et al. Repeated dose budesonide/formoterol compared to salbutamol in adult asthma: A randomised cross-over trial. Eur Respir J 2022.</a></li><li class="breakAll">British Thoracic Society and
Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma: A national clinical guideline. https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2016/ (Accessed on December 21, 2017).</li><li><a class="nounderline abstract_t">Gibson PG, Powell H, Ducharme F. Long-acting beta2-agonists as an inhaled corticosteroid-sparing agent for chronic asthma in adults and children. Cochrane Database Syst Rev 2005; :CD005076.</a></li><li><a class="nounderline abstract_t">Wilding P, Clark M, Thompson Coon J, et al. Effect of long-term treatment with salmeterol on asthma control: a double blind, randomised crossover study. BMJ 1997; 314:1441.</a></li><li><a class="nounderline abstract_t">Mcivor RA, Pizzichini E, Turner MO, et al. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998; 158:924.</a></li><li><a class="nounderline abstract_t">Deeks ED. Olodaterol: a review of its use in chronic obstructive pulmonary disease. Drugs 2015; 75:665.</a></li><li><a class="nounderline abstract_t">Lötvall J, Bateman ED, Bleecker ER, et al. 24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids. Eur Respir J 2012; 40:570.</a></li><li><a class="nounderline abstract_t">Sterling R, Lim J, Frith L, et al. Efficacy and optimal dosing interval of the long-acting beta₂ agonist, vilanterol, in persistent asthma: a randomised trial. Respir Med 2012; 106:1110.</a></li><li><a class="nounderline abstract_t">Kew KM, Dias S, Cates CJ. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database Syst Rev 2014; :CD010844.</a></li><li><a class="nounderline abstract_t">Geake JB, Dabscheck EJ, Wood-Baker R, Cates CJ. Indacaterol, a once-daily beta2-agonist, versus twice-daily beta₂-agonists or placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015; 1:CD010139.</a></li><li><a class="nounderline abstract_t">Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med 2010; 362:1169.</a></li><li><a class="nounderline abstract_t">Lemanske RF Jr, Busse WW. The US Food and Drug Administration and long-acting beta2-agonists: the importance of striking the right balance between risks and benefits of therapy? J Allergy Clin Immunol 2010; 126:449.</a></li><li><a class="nounderline abstract_t">Cates CJ, Cates MJ. Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2012; :CD006923.</a></li><li><a class="nounderline abstract_t">Rodrigo GJ, Moral VP, Marcos LG, Castro-Rodriguez JA. Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma. A systematic review. Pulm Pharmacol Ther 2009; 22:9.</a></li><li><a class="nounderline abstract_t">Cates CJ, Cates MJ. Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2008; :CD006363.</a></li><li><a class="nounderline abstract_t">Hausdorff WP, Caron MG, Lefkowitz RJ. Turning off the signal: desensitization of beta-adrenergic receptor function. FASEB J 1990; 4:2881.</a></li><li><a class="nounderline abstract_t">Pearlman DS, Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med 1992; 327:1420.</a></li><li><a class="nounderline abstract_t">Cheung D, Timmers MC, Zwinderman AH, et al. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992; 327:1198.</a></li><li><a class="nounderline abstract_t">Cockcroft DW, McParland CP, Britto SA, et al. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 1993; 342:833.</a></li><li><a class="nounderline abstract_t">Grove A, Lipworth BJ. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet 1995; 346:201.</a></li><li><a class="nounderline abstract_t">Aziz I, Hall IP, McFarlane LC, Lipworth BJ. Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma. J Allergy Clin Immunol 1998; 101:337.</a></li><li><a class="nounderline abstract_t">Haney S, Hancox RJ. Rapid onset of tolerance to beta-agonist bronchodilation. Respir Med 2005; 99:566.</a></li><li><a class="nounderline abstract_t">Dweik RA, Sorkness RL, Wenzel S, et al. Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma. Am J Respir Crit Care Med 2010; 181:1033.</a></li><li><a class="nounderline abstract_t">Bonini M, Permaul P, Kulkarni T, et al. Loss of salmeterol bronchoprotection against exercise in relation to ADRB2 Arg16Gly polymorphism and exhaled nitric oxide. Am J Respir Crit Care Med 2013; 188:1407.</a></li><li class="breakAll">Nelson HS. Beta-adrenergic agonists. In: Middleton's Allergy: Principles and Practice, 6th Ed, Adkinson NF, Yunginger JW, Busse WW, et al (Eds), Mosby, St Louis 2003. p.803.</li><li><a class="nounderline abstract_t">Jenne JW, Valcarenghi G, Druz WS, et al. Comparison of tremor responses to orally administered albuterol and terbutaline. Am Rev Respir Dis 1986; 134:708.</a></li><li><a class="nounderline abstract_t">Kurisu S, Inoue I, Kawagoe T, et al. Assessment of medications in patients with tako-tsubo cardiomyopathy. Int J Cardiol 2009; 134:e120.</a></li><li><a class="nounderline abstract_t">Osuorji I, Williams C, Hessney J, et al. Acute stress cardiomyopathy following treatment of status asthmaticus. South Med J 2009; 102:301.</a></li><li><a class="nounderline abstract_t">Rennyson SL, Parker JM, Symanski JD, Littmann L. Recurrent, severe, and rapidly reversible apical ballooning syndrome in status asthmaticus. Heart Lung 2010; 39:537.</a></li><li><a class="nounderline abstract_t">Leslie D, Coats PM. Salbutamol-induced diabetic ketoacidosis. Br Med J 1977; 2:768.</a></li><li><a class="nounderline abstract_t">van den Berg BT, Louwerse RT, Luiken GJ, et al. Hypokalaemia in healthy volunteers after single and multiple doses of formoterol or salbutamol. Clin Drug Investig 1998; 15:523.</a></li><li><a class="nounderline abstract_t">Berger WE. The use of inhaled formoterol in the treatment of asthma. Ann Allergy Asthma Immunol 2006; 97:24.</a></li><li><a class="nounderline abstract_t">Guhan AR, Cooper S, Oborne J, et al. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax 2000; 55:650.</a></li></ol></div><div id="topicVersionRevision">Topic 558 Version 42.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23348973" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : β2-agonist therapy in lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16263481" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Beta2-adrenoceptors: mechanisms of action of beta2-agonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16263481" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Beta2-adrenoceptors: mechanisms of action of beta2-agonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33280709" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16387578" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16387578" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16387578" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3565860" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Frequent parenteral terbutaline in the treatment of status asthmaticus in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2927990" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : High-versus low-dose, frequently administered, nebulized albuterol in children with severe, acute asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8365298" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A comparison of albuterol administered by metered dose inhaler (and holding chamber) or wet nebulizer in acute asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8449049" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Emergency department treatment of severe asthma. Metered-dose inhaler plus holding chamber is equivalent in effectiveness to nebulizer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3974097" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Comparison of the acute cardiopulmonary effects of oral albuterol, metaproterenol, and terbutaline in asthmatics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3510540" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Treatment of acute asthma. Is combination therapy with sympathomimetics and methylxanthines indicated?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2754149" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Epinephrine improves expiratory flow rates in patients with asthma who do not respond to inhaled metaproterenol sulfate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/594935" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Intravenous or inhaled salbutamol in severe acute asthma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7014120" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Comparison of intravenous and inhaled terbutaline in the treatment of asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8004299" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Nebulized versus intravenous albuterol in hypercapnic acute asthma. A multicenter, double-blind, randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23235685" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Addition of intravenous beta(2)-agonists to inhaled beta(2)-agonists for acute asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1956735" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Cardiotoxicity during treatment of severe childhood asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9024371" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Randomised trial of intravenous salbutamol in early management of acute severe asthma in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17572517" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Comparison of intravenous terbutaline versus normal saline in pediatric patients on continuous high-dose nebulized albuterol for status asthmaticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12406669" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Comparison of the bronchodilating effects of inhaled formoterol, salmeterol and salbutamol in asthmatic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11587972" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Long-acting inhaled beta(2)-agonist therapy in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11587972" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Long-acting inhaled beta(2)-agonist therapy in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31981105" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : SABINA: An Overview of Short-Actingβ2-Agonist Use in Asthma in European Countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31949111" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Overuse of short-actingβ2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34561293" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Short-actingβ2-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35364341" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Short-Acting Beta-2-Agonist Exposure and Severe Asthma Exacerbations: SABINA Findings From Europe and North America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34718211" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15007354" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : (S)-Albuterol activates pro-constrictory and pro-inflammatory pathways in human bronchial smooth muscle cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18219836" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Long-term safety study of levalbuterol administered via metered-dose inhaler in patients with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10200010" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10883742" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Dose-response evaluation of levalbuterol versus racemic albuterol in patients with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18692886" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A cumulative dose study of levalbuterol and racemic albuterol administered by hydrofluoroalkane-134a metered-dose inhaler in asthmatic subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9847435" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11692096" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11692088" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Levalbuterol and racemic albuterol: are there therapeutic differences?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10368697" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Levalbuterol for asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12970007" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : An evaluation of nebulized levalbuterol in stable COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15988423" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3106449" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2932989" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Influence of albuterol, cromolyn sodium and ipratropium bromide on the airway and circulating mediator responses to allergen bronchial provocation in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1978163" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Protection against allergen-induced asthma by salmeterol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6418561" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Pretreatment of exercise-induced asthma in children using disodium cromoglycate and fenoterol inhalation powder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3113295" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A comparison of inhaled albuterol and cromolyn in the prophylaxis of exercise-induced bronchospasm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2523921" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Comparative efficacy of salbutamol, ipratropium, and cromoglycate in the prevention of bronchospasm induced by exercise and hyperosmolar challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1969985" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Hypothesis: exercise-induced asthma as a vascular phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1440473" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The airway microvasculature and exercise induced asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1346340" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The use of beta-agonists and the risk of death and near death from asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5654963" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Exercise-induced bronchospasm: evaluation of metaproterenol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1351489" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Protective effect and duration of action of inhaled formoterol and salbutamol on exercise-induced asthma in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1355645" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Prevention of exercise induced asthma by inhaled salmeterol xinafoate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7913549" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34699967" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Albuterol/budesonide for the treatment of exercise-induced bronchoconstriction in patients with asthma: The TYREE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27582089" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Vilanterol and fluticasone furoate for asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16235409" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16235410" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15502112" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20197425" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20159250" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Safety of formoterol in patients with asthma: combined analysis of data from double-blind, randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23543548" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20176343" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Long-acting beta-agonists with and without inhaled corticosteroids and catastrophic asthma events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23744625" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24504983" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26949137" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22281166" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The relationship between combination inhaled corticosteroid and long-actingβ-agonist use and severe asthma exacerbations in a diverse population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27579634" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27579635" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Serious Asthma Events with Budesonide plus Formoterol vs. Budesonide Alone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29949492" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Combined Analysis of Asthma Safety Trials of Long-Actingβ2-Agonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18768573" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Long-acting beta-agonists: a review of formoterol safety data from asthma clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19797669" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Risk of mortality associated with formoterol: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8098238" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16424409" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17253458" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17253458" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Serious asthma outcomes with mometasone furoate plus formoterol versus mometasone alone</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Serious asthma outcomes with mometasone furoate plus formoterol versus mometasone alone</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35115339" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Repeated dose budesonide/formoterol compared to salbutamol in adult asthma: A randomised cross-over trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35115339" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Repeated dose budesonide/formoterol compared to salbutamol in adult asthma: A randomised cross-over trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16235393" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Long-acting beta2-agonists as an inhaled corticosteroid-sparing agent for chronic asthma in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9167559" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Effect of long-term treatment with salmeterol on asthma control: a double blind, randomised crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9731027" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Potential masking effects of salmeterol on airway inflammation in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25773742" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Olodaterol: a review of its use in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22362859" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : 24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22520084" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Efficacy and optimal dosing interval of the long-acting beta₂agonist, vilanterol, in persistent asthma: a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24671923" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25575340" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Indacaterol, a once-daily beta2-agonist, versus twice-daily beta₂-agonists or placebo for chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20181964" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : The FDA and safe use of long-acting beta-agonists in the treatment of asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20692690" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : The US Food and Drug Administration and long-acting beta2-agonists: the importance of striking the right balance between risks and benefits of therapy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22513944" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Regular treatment with formoterol for chronic asthma: serious adverse events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19026757" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma. A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18646149" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Regular treatment with salmeterol for chronic asthma: serious adverse events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2165947" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Turning off the signal: desensitization of beta-adrenergic receptor function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1357554" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1357550" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8104272" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Regular inhaled salbutamol and airway responsiveness to allergen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7616798" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9525449" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15823453" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Rapid onset of tolerance to beta-agonist bronchodilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20133930" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24228710" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Loss of salmeterol bronchoprotection against exercise in relation to ADRB2 Arg16Gly polymorphism and exhaled nitric oxide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24228710" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Loss of salmeterol bronchoprotection against exercise in relation to ADRB2 Arg16Gly polymorphism and exhaled nitric oxide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3767127" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Comparison of tremor responses to orally administered albuterol and terbutaline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18499288" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Assessment of medications in patients with tako-tsubo cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19204641" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Acute stress cardiomyopathy following treatment of status asthmaticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20561882" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Recurrent, severe, and rapidly reversible apical ballooning syndrome in status asthmaticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/410474" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Salbutamol-induced diabetic ketoacidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18370510" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Hypokalaemia in healthy volunteers after single and multiple doses of formoterol or salbutamol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16892777" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : The use of inhaled formoterol in the treatment of asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10899240" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
